(2,4-dimethylthiophen-3-yl)methanol | 63826-85-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2,4-dimethylthiophen-3-yl)methanol
• 英文别名: 2,4-dimethylthiophene-3-carboxaldehyde；2,4-dimethylthiophene-3-carbaldehyde
• CAS: 63826-85-7
• 化学式: C₇H₈OS
• 分子量: 140.206
• InChiKey: YWFAGBQENUFCPJ-UHFFFAOYSA-N

物化性质

• 沸点：
  221.1±35.0 °C(Predicted)
• 密度：
  1.138±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2,4-dimethylthiophen-3-yl)methanol 在 sodium borohydrid 作用下， 以 乙醇 为溶剂， 生成 (2,4-dimethylthiophen-3-yl)methanol
  参考文献：
  名称：

  Polyene compounds

  摘要：

  揭示了作为抗肿瘤药物有用的9-取代或未取代噻吩基-3,7-二甲基-诺纳-2,4,6,8-四烯衍生物，以及它们的制备方法和新型中间体。

  公开号：

  US04061656A1
• 作为产物：
  描述：

  (2,4-dimethylthiophen-3-yl)methanol 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以38%的产率得到(2,4-dimethylthiophen-3-yl)methanol
  参考文献：
  名称：

  [EN] PYRAZOLE AMIDE DERIVATIVE
  [FR] DÉRIVÉ DE PYRAZOLE AMIDE

  摘要：

  本发明涉及一种新型化合物，具有抑制RORγ活性的功能。本发明还涉及包括该化合物的药物组合物，以及在治疗或预防自身免疫疾病、炎症性疾病、代谢性疾病或癌症疾病中使用该化合物的用途。

  公开号：

  WO2015129926A1

文献信息

• 4-\x9b(thien-3-yl)methyl!-imidazole analgesics
  申请人：Ortho Pharmaceutical Corporation

  公开号：US05750720A1

  公开（公告）日：1998-05-12

  Described herein are 4-\x9b(thien-3-yl)methyl!-imidazoles of the formula: ##STR1## wherein R is hydrogen or methyl, and X is C.sub.1-4 alkyl, bromine or chlorine; or ##STR2## wherein Y is hydrogen, C.sub.1-4 alkyl, bromine or chlorine, and Z is C.sub.1-4 4alkyl, bromine or chlorine which have exceptional analgesic activity.

  本文描述的是公式为4-（噻吩-3-基）甲基-咪唑的化合物：其中R为氢或甲基，X为C.sub.1-4烷基，溴或氯；或者其中Y为氢，C.sub.1-4烷基，溴或氯，Z为C.sub.1-4烷基，溴或氯的化合物，具有出色的镇痛活性。
• Pyrazole Amide Derivative
  申请人：AMGEN INC.

  公开号：US20150266824A1

  公开（公告）日：2015-09-24

  The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

  本发明涉及一种新型化合物，具有抑制RORγ活性的功能。本发明还涉及包含该化合物的药物组合物，以及使用该化合物治疗或预防自身免疫性疾病、炎症性疾病、代谢性疾病或癌症疾病的用途。
• α₂ Adrenoceptor Agonists as Potential Analgesic Agents. 3. Imidazolylmethylthiophenes
  作者：Robert E. Boyd、C. Royce Rasmussen、Jeffery B. Press、Robert B. Raffa、Ellen E. Codd、Charlene D. Connelly、Quan S. Li、Rebecca P. Martinez、Martin A. Lewis、Harold R. Almond、Allen B. Reitz

  DOI：10.1021/jm0003891

  日期：2001.3.1

  A series of imidazolylmethylthiophenes has been prepared and evaluated as ligands for the at adrenoceptor. These compounds were tested in two animal models that are predictive of analgesic activity in humans. The 3-thienyl compounds were generally the most potent, particularly those with substitution in the 4-position. A subset of the most active compounds was further evaluated for adverse cardiovascular effects in the anesthetized rat model. In addition to excellent binding at the alpha (2D) adrenoceptor, the 4-bromo analogues 20e and 21e were very active in the rat abdominal irritant test (RAIT) with ED50 doses of 0.38 and 0.31 mg/kg, respectively. We constructed a pharmacophore model based on the biological activity of the present series, dexmedetomidine (1), and conformationally restrained analogues 3 and 4.
• 4- (THIEN-3-YL)METHYL] IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP0954521A1

  公开（公告）日：1999-11-10
• NOVEL IMIDAZOPYRIDINE COMPOUNDS WITH THERAPEUTIC EFFECT
  申请人：AstraZeneca AB

  公开号：EP1421083A1

  公开（公告）日：2004-05-26